The Correlation of KRAS Gene Expression and P53 Immunoexpression In Colorectal Adenocarcinoma

Authors

  • Meike Rachmawati Department of Pathology Anatomy, Oncology and Stem Cells Research Centre, Padjadjaran University, Dr. Hasan Sadikin Hospital, Bandung, Indonesia; Department of Pathology Anatomy, Universitas Islam Bandung, Bandung, Indonesia
  • Herry Yulianti Department of Pathology Anatomy, Oncology and Stem Cells Research Centre, Padjadjaran University, Dr. Hasan Sadikin Hospital, Bandung, Indonesia
  • Bethy S. Hernowo Department of Pathology Anatomy, Oncology and Stem Cells Research Centre, Padjadjaran University, Dr. Hasan Sadikin Hospital, Bandung, Indonesia
  • Sri Suryanti Department of Pathology Anatomy, Oncology and Stem Cells Research Centre, Padjadjaran University, Dr. Hasan Sadikin Hospital, Bandung, Indonesia
  • Indra Wijaya Department of Interne Medicine, Padjadjaran University, Dr. Hasan Sadikin, Hospital Bandung, Bandung, Indonesia
  • Nur Rahadiani Department of Pathology Anatomy, Indonesia University, Cipto Mangun Kusumo Hospital, Jakarta, Indonesia
  • Didik S. Heriyanto Department of Pathology Anatomy, Gajah Mada University, Sardjito Hospital, Jogjakarta, Indonesia
  • Irianiwati Irianiwati Department of Pathology Anatomy, Gajah Mada University, Sardjito Hospital, Jogjakarta, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2019.549

Keywords:

KRAS, p53, Adenocarcinoma Colorectal (ADCCR)

Abstract

BACKGROUND: Colorectal Adenocarcinoma (ADCCR) is the third most cancer not only in the world but also in Indonesia. There were 623 cases of ADCCR at Dr Hasan Sadikin hospital within 2015-2017. Both KRAS and TP53 mutation are known as genes which involve in carcinogenesis through the same pathway, namely the chromosomal instability pathway. In West Java, researches focusing on mutation KRAS and p53 also a correlation between both biomarkers among ADCCR patients are still limited.
AIM: Therefore, this research aimed to perceive a correlation between KRAS gene expression with p53 immunoexpression in ADCCR.
METHODS: Cross section research design was performed to 62 cases of ADCCR as paraffin block taken from 4 hospitals in West Java, including Dr Hasan Sadikin hospital Bandung, Santosa hospital Bandung, Borromeus hospital Bandung and Syamsudin hospital Sukabumi from January 1st 2014 to 31s November 2018. KRAS mutation gene data taken from secondary data at molecular laboratory in Ciptomangunkusumo Hospital Jakarta and Dr Sardjito Hospital Jogjakarta, while the detection of p53 immunoexpression data using immunohistochemical staining was carried out in the Laboratorium of Anatomical Pathology of Padjadjaran University (Dr Hasan Sadikin Hospital). All data were analysed using Chi-Square test with p-value < 0,05 of significant level then proceeded with Stata ver.11 for windows.
RESULTS: The results of this study showed that KRAS gene expressions from 62 sample consist of 39 wild type KRAS (62.39%) and 23 mutant KRAS (37.1%). The p53 immunoexpression consists of 27 negative cases (non-mutant p53) and 35 mutant p53, which includes 10 cases as focal expression (16.33%) and 25 cases as diffuse expressions (40.33%). There is a significant association between KRAS gene expression and p53 immunoexpressions in ADCCR (p = 0.04), with mild positive correlation (Rho 0.28).
CONCLUSION: This study concluded that KRAS and p53 mutations are involved in carcinogenesis, and the p53 mutation is a more dominant risk factor than KRAS mutation among West Java people. P53 mutations with diffuse pattern tend to express mutant KRAS while p53 negative and having a focal pattern tend to express wt KRAS.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. World Health Organization; 2010:131-181.

Mahasneh A, Al-Shaheri F, Jamal E. Molecular biomarkers for early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates. Experimental and molecular pathology. 2017; 102(3): 475-83. https://doi.org/10.1016/j.yexmp.2017.05.005 PMid:28506769

Kementrian Kesehatan RI. Panduan Penatalaksanaan Kanker kolorektal. 2015; 1-67.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. https://doi.org/10.3322/caac.21492 PMid:30207593

Testa U, Pelosi E, Castelli G. Colorectal cancer: genetic abnormalities, tumour progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Medical Sciences. 2018; 6(2):31. https://doi.org/10.3390/medsci6020031 PMid:29652830 PMCid:PMC6024750

Kumar V, Abbas AK, Aster JC. Robbins basic pathology. ed-10. Elsevier Health Sciences; 2017:261-71.

Abdullah M, Sudoyo AW, Utomo AR, Fauzi A, Rani AA. Molecular profile of colorectal cancer in Indonesia: is there another pathway?. Gastroenterology and Hepatology from bed to bench. 2012; 5(2):71-5.

Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World journal of gastroenterology: WJG. 2012; 18(37):5171

Sui X, Zhu J, Tang H, Wang C, Zhou J, Han W, Wang X, Fang Y, Xu Y, Li D, Chen R. p53 controls colorectal cancer cell invasion by inhibiting the NF-κB-mediated activation of Fascin. Oncotarget. 2015; 6(26):22869. https://doi.org/10.18632/oncotarget.5137 PMid:26362504 PMCid:PMC4673205

Chaar I, Amara S, Elamine OE, Khiari M, Ounissi D, Khalfallah T, Mzabi S, Bouraoui S. Biological significance of promoter hypermethylation of p14/ARF gene: relationships to p53 mutational status in Tunisian population with colorectal carcinoma. Tumor Biology. 2014; 35(2):1439-49. https://doi.org/10.1007/s13277-013-1198-9 PMid:24065196 PMCid:PMC3932170

Levi M, Prayogi G, Sastranagara F, Sudianto E, Widjajahakim G, Gani W, Mahanadi A, Agnes J, Khairunisa BH, Utomo AR. Clinicopathological associations of K-RAS and N-RAS mutations in Indonesian colorectal cancer cohort. Journal of gastrointestinal cancer. 2018; 49(2):124-31. https://doi.org/10.1007/s12029-016-9901-x PMid:28044264

Van Cutsem E, Kohne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29(15):2011-9. https://doi.org/10.1200/JCO.2010.33.5091 PMid:21502544

Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T, Lozano G. Multiple stress signals activate mutant p53 in vivo. Cancer research. 2011; 71(23):7168-75. https://doi.org/10.1158/0008-5472.CAN-11-0459 PMid:21983037 PMCid:PMC3320147

Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. The Journal of pathology. 2010; 222(2):129-37. https://doi.org/10.1002/path.2748 PMid:20662002

Ross JS. Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective. Archives of pathology & laboratory medicine. 2012; 136(10):1298-307. https://doi.org/10.5858/arpa.2011-0478-RA PMid:22272560

Al-Kuraya KS. KRAS and TP53 mutations in colorectal carcinoma. Saudi journal of gastroenterology. 2009; 15(4):21-7. https://doi.org/10.4103/1319-3767.56087 PMid:19794264 PMCid:PMC2981835

Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi M. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. International journal of molecular sciences. 2017; 18(1):197. https://doi.org/10.3390/ijms18010197 PMid:28106826 PMCid:PMC5297828

Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J, Kim J. Prognostic and predictive roles of KRAS mutation in colorectal cancer. International journal of molecular sciences. 2012; 13(10):12153-68. https://doi.org/10.3390/ijms131012153 PMid:23202889 PMCid:PMC3497263

Nyiraneza C, Jouret-Mourin A, Kartheuser A, Camby P, Plomteux O, Detry R, Dahan K, Sempoux C. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer. Human pathology. 2011; 42(12):1897-910. https://doi.org/10.1016/j.humpath.2010.06.021 PMid:21665242

Knickelbein K, Zhang L. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes & diseases. 2015; 2(1):4-12. https://doi.org/10.1016/j.gendis.2014.10.002 PMid:25815366 PMCid:PMC4372129

Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, et al. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Annals of surgical oncology. 2013; 20(7):2166-71. https://doi.org/10.1245/s10434-013-2910-0 PMid:23456389 PMCid:PMC5584556

Muller PAJ, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer cell. 2014; 25(3):304-17. https://doi.org/10.1016/j.ccr.2014.01.021 PMid:24651012 PMCid:PMC3970583

Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Molecular and cellular biology. 2007; 27(23):8284-95. https://doi.org/10.1128/MCB.00050-07 PMid:17908790 PMCid:PMC2169174

Published

2019-07-09

How to Cite

1.
Rachmawati M, Yulianti H, Hernowo BS, Suryanti S, Wijaya I, Rahadiani N, Heriyanto DS, Irianiwati I. The Correlation of KRAS Gene Expression and P53 Immunoexpression In Colorectal Adenocarcinoma. Open Access Maced J Med Sci [Internet]. 2019 Jul. 9 [cited 2021 Dec. 7];7(12):1940-5. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2019.549

Issue

Section

A - Basic Science

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.